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ABSTRACT Colonization of the upper respiratory tract with Streptococcus pneumoniae
is the precursor of pneumococcal pneumonia and invasive disease. Following exposure,
however, it is unclear which human immune mechanisms determine whether a patho-
gen will colonize. We used a human challenge model to investigate host-pathogen
interactions in the first hours and days following intranasal exposure to Streptococcus
pneumoniae. Using a novel home sampling method, we measured early immune
responses and bacterial density dynamics in the nose and saliva after volunteers were
experimentally exposed to pneumococcus. Here, we show that nasal colonization can
take up to 24h to become established. Also, the following two distinct bacterial clear-
ance profiles were associated with protection: nasal clearers with immediate clearance
of bacteria in the nose by the activity of pre-existent mucosal neutrophils and saliva
clearers with detectable pneumococcus in saliva at 1 h post challenge and delayed
clearance mediated by an inflammatory response and increased neutrophil activity 24h
post bacterial encounter. This study describes, for the first time, how colonization with
a bacterium is established in humans, signifying that the correlates of protection
against pneumococcal colonization, which can be used to inform design and test-
ing of novel vaccine candidates, could be valid for subsets of protected individuals.
IMPORTANCE Occurrence of lower respiratory tract infections requires prior coloniza-
tion of the upper respiratory tract with a pathogen. Most bacterial infection and col-
onization studies have been performed in murine and in vitro models due to the
current invasive sampling methodology of the upper respiratory tract, both of which
poorly reflect the complexity of host-pathogen interactions in the human nose. Self-
collecting saliva and nasal lining fluid at home is a fast, low-cost, noninvasive, high-
frequency sampling platform for continuous monitoring of bacterial encounter at
defined time points relative to exposure. Our study demonstrates for the first time
that, in humans, there are distinct profiles of pneumococcal colonization kinetics, dis-
tinguished by speed of appearance in saliva, local phagocytic function, and acute
mucosal inflammatory responses, which may either recruit or activate neutrophils.
These data are important for the design and testing of novel vaccine candidates.
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The human respiratory tract is a major site of contact with aerosolized bacteria.Acute respiratory tract infections are common, and pneumonia causes more than
1.3 million child deaths annually (1, 2) as well as frequent hospitalizations in at-risk
groups, such as the elderly, people with chronic lung disease, and asthmatics (3).
The first stage of such infections is the successful colonization of the upper respira-
tory tract by the pathogen (4). Streptococcus pneumoniae, the major bacterial cause
of pneumonia, inhabits the nasopharynx of 40 to 95% of young children and 10 to
25% of adults without causing disease (5–7). Colonization is usually asymptomatic in
adults but can be associated with mild rhinitis symptoms in children (8). Different sero-
types of pneumococcus may inhabit the nasopharynx at varying densities (9, 10).
Colonization may continue for a period of weeks or months, and S. pneumoniae coloni-
zation is eliminated and reacquired many times during life (11). As pneumococcal colo-
nization is the primary reservoir for transmission (12) and a prerequisite of invasive dis-
ease (13), its control is key to preventing disease. Importantly, which factors determine
whether exposure to S. pneumoniae leads to colonization have not been completely
identified in humans. Factors such as host age, immune status, virus coinfection, expo-
sure to antibiotics, smoking, and overcrowded living conditions have all been associ-
ated with increased susceptibility to colonization (14–16).
The Experimental Human Pneumococcal Challenge (EHPC) model allows for the
rapid, safe, and accurate study of bacterial encounter at the nasopharynx in humans
(17). In the EHPC model, the precise dose and timing of infection are known.
Individuals are inoculated with live type 6B pneumococcus, and pneumococcal coloni-
zation (detection and density) is assessed by nasal washes collected from 48h onwards
post exposure (17). After this point, approximately 40 to 50% of individuals become
carriers, but the early kinetics of bacterial clearance or colonization onset have not
been assessed. In this study, healthy adult volunteers were challenged with S. pneumo-
niae, after which they self-collected saliva and nasal lining fluid (NLF) samples for bac-
terial kinetics and mucosal immune monitoring in the first 48 h. We compared non-
colonized and colonized subjects to identify potential correlates of protection and to
define the kinetics of colonization. Our hypothesis was that mucosal innate responses
would be predictive of protection against colonization, and the movement of bacteria
from the nose (site of exposure) to the saliva within the first 48 h would be associated
with less effective immunity and potentially with colonization in adults.
RESULTS
Home sampling method can be used to collect samples at defined time points.
Sixty-three volunteers aged 18 to 49 years were screened for preexisting colonization
with pneumococcus, all of whom were noncolonized, and subsequently inoculated
with 6B pneumococcus as previously described (17). Colonization status was defined
by classical microbiology culture of S. pneumoniae serotype 6B in nasal wash samples
collected at days 2, 6, 9, 14, 21, and 27 post exposure. Volunteers with negative sam-
ples at all time points were defined as culture-negative, and those with a positive sam-
ple at any time point were classified as culture-positive. Following exposure, 41 volun-
teers remained culture-negative (41/63, 65.1%) and 22 became culture-positive (see
Table S1 in the supplemental material). Colonization status was confirmed by S. pneu-
moniae 6A/B capsule-specific and lytA-specific quantitative PCR (qPCR) in nasal wash to
ensure that we did not miss low-density colonizers (18). Only one culture-negative vol-
unteer showed a low positive signal (threshold cycle [CT] = 37) at day 6 post S. pneumo-
niae exposure.
Saliva and NLF samples were obtained before exposure (time = 0 h, baseline)
(Fig. 1A). Volunteers collected their own saliva into preprepared tubes at 1, 2, 4, 8, 24,
36, and 48 h, and NLF (by nasosorption strip) (19) at 24 and 48 h. A subset of 33 volun-
teers self-collected in addition NLF samples at 4 and 8 h to assess very early nasal dy-
namics (see Fig. S1 in the supplemental material). To monitor compliance, volunteers
were instructed to record sample collection times using their mobile phones and send
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FIG 1 Kinetics of early pneumococcal detection in saliva. (A) Schematic representation of sample collection design. Saliva and NLF
samples were collected before exposure, T= 0 h (baseline), in clinic. Volunteers were asked to self-collect saliva at 1, 2, 4, 8, 24, 36,
(Continued on next page)
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pictures of the collected sample to the research team at the time of sample collection
(see Fig. S2A in the supplemental material). Samples from two volunteers were
excluded (3.2%) due to incorrect storage of samples, as at least half of their samples
were stored at room temperature (Fig. S2B). Therefore, data from 61 volunteers were
evaluated in this study as follows: 40 culture-negative and 21 culture-positive volun-
teers (Table S1). This high rate of compliance (61/63, 96.8%) indicates the successful
application of this self-sampling method.
Raw and culture-enriched DNA extractions in saliva were complementary for
pneumococcal detection in saliva. To detect S. pneumoniae presence, pneumococcal
genomic DNA was extracted from both raw and culture-enriched (blood agar plate
with gentamicin) saliva samples, as the latter might lead to increased pneumococcal
detection in saliva (20, 21). In total, 83 time points with S. pneumoniae present were
detected using an S. pneumoniae 6A/B capsule-specific qPCR (22): 32 only in raw sam-
ples, 24 only in culture-enriched samples, and 27 in both (Fig. S2C). Consequently, sam-
ples with a positive result using either method were included in further analyses. As
expected, S. pneumoniae density from culture-enriched samples was significantly
higher (lower CT values) than that from raw samples (Fig. S2D).
Two distinct profiles of bacterial clearance kinetics associated with protection
against colonization. To investigate the kinetics of S. pneumoniae clearance and
establishment, we assessed the presence of pneumococcal DNA in saliva in the first
48 h after exposure (Fig. 1A). At 1 h post challenge, S. pneumoniae DNA was detected
in the saliva of 16/40 (40%) culture-negative volunteers and 0/21 (0%) culture-positive
volunteers (Fig. 1B and C; ***, P=0.0005, Fisher Exact test). Thus, a subset of culture-
negative volunteers exhibited rapid movement of S. pneumoniae to the saliva follow-
ing exposure, which could suggest that two distinct profiles of protection against
colonization exist. We named these two groups “nasal clearers” (individuals with no de-
tectable S. pneumoniae DNA in 1 h post exposure saliva samples) and “saliva clearers”
(individuals with detectable S. pneumoniae DNA in 1 h post exposure saliva samples).
Saliva clearers showed a peak of S. pneumoniae density (DNA copies/ml saliva) at 1 h af-
ter exposure, followed by a gradual decrease of S. pneumoniae density after 1 h. Nasal
clearers showed similar levels of S. pneumoniae density between 2 and 12 h (Fig. 1D).
Establishment of pneumococcal colonization takes up to 24h. Among the cul-
ture-positive volunteers, S. pneumoniae DNA was not detected in any 1 h saliva sam-
ples (Fig. 1B and C). At 2, 4, and 8 h, detection of S. pneumoniae DNA was not different
from that of those who become culture-negative. At 24 h, however, S. pneumoniae
DNA was detected in saliva of 8/21 (38.1%) culture-positive volunteers but only 2/40
(5%) of culture-negative volunteers (Fig. 1B and C; **, P= 0.002). Moreover, the propor-
tion of culture-positives with detectable S. pneumoniae DNA in the saliva continued to
increase to 14/21 (76.2%) at 48 h (Fig. 1B; ****, P, 0.0001 compared to culture-nega-
tives). At the same time, the mean density of S. pneumoniae DNA started increasing in
culture-positive volunteers from 24h onwards (Fig. 1D). This suggests that bacterial
FIG 1 Legend (Continued)
and 48 h and NLF at 24 and 48h post exposure. *, A subgroup of 33 individuals also collected NLF at 4 and 8 h post exposure to
assess very early nasal microbiological and immunological dynamics. (B) Frequency of volunteers with detected S. pneumoniae 6B
pneumococcus in saliva. Pneumococcal DNA presence in saliva was determined by S. pneumoniae (Spn) 6A/B qPCR. The number of
volunteers with S. pneumoniae 6B presence (CT , 40) in each time point is expressed as a percentage (%) of the total number of
volunteers for culture-positive and culture-negative groups in red and black, respectively. Statistical significance based on Fisher’s
exact test. T= 1 h, ***, P= 0.0005; T= 24 h, **, P= 0.002; T= 36 h, *, P= 0.011; and T= 48h, ****, P, 0.0001. (C) Heatmap showing
individual saliva profiles. Presence of pneumococcal DNA detected from raw and/or culture-enriched extraction is depicted. Three
distinct saliva profiles were defined. Culture-positive, volunteers who were identified to be experimentally colonized with
pneumococcus at day 2 or later using classical microbiology (red, n=21). Culture-negatives were divided into two groups as
follows: saliva clearers, volunteers with detectable S. pneumoniae in saliva at 1 h after exposure (blue, n= 16) and nasal clearers,
volunteers without detectable S. pneumoniae in saliva at 1 h after exposure (green, n= 24). (D) Density levels of pneumococcal 6A/B
PCR in saliva (culture-positives, n=21; saliva clearers, n= 16; and nasal clearers, n= 24). S. pneumoniae 6B density was expressed as
DNA copies per volume (ml) of saliva. Only DNA from extractions without culture enrichment were included, as enrichment modifies
density values (see also Fig. S2D). All samples with undetectable S. pneumoniae were set to 0 CFU/ml. Data were log transformed
after adding 1 to all values to allow transformation of 0 values. Individual volunteers and the mean of log-transformed values are
shown.
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amplification only starts occurring after this period and that S. pneumoniae colonization
following experimental exposure is a gradual colonization process that takes at least
24h.
Bacterial DNA detection in the nose post exposure. We then evaluated the pres-
ence of pneumococcal DNA in the nasal lining fluid during the first 48 h post exposure
by qPCR and stratified this by colonization status determined by conventional bacterial
culture at later time points. At 4 and 8h, S. pneumoniae DNA was detected in almost all
NLF samples (Fig. 2A and B). At 24 and 48 h post exposure, S. pneumoniae DNA was
detected in nasal lining fluid from 27/58 (47%) and 15/59 (25%) total volunteers,
respectively. When stratified, there was no difference in DNA detection rates in the first
2 days between those who were subsequently colonized and those who were not
(Fig. 2A to C). An absence of detectable bacterial DNA at 24 h suggests bacterial clear-
ance or migration posteriorly in the nasopharynx or attachment and internalization at
the epithelium (Fig. 2A and B).
Pneumococcal agglutination was not associated with early pneumococcal
profiles. Agglutination of pneumococcus by polysaccharide 6B (PS6B)-specific IgG
antibodies has been previously shown to protect against 6B pneumococcus coloniza-
tion in the context of pneumococcal conjugate vaccination (23). Also, mucus is known
to be able to trap pathogens (24) and to bind pneumococcus through carbohydrate
motifs (25). We hypothesized that the saliva clearer group had a superior agglutination
capacity, leading to rapid detection of S. pneumoniae DNA in saliva and, therefore,
measured agglutination capacity in baseline nasal wash samples (Fig. 2D). We also
associated agglutination capacity with concentrations of mucin 5AC (MUC5AC) and S.
pneumoniae 6B polysaccharide-specific IgG antibodies (PS6B) in baseline nasal wash
samples (Fig. 3D and E). Baseline nasal wash agglutination capacity was correlated sig-
nificantly with high levels of MUC5AC (Fig. 3F) but not with PS6B-specific IgG levels
(Fig. 3G). However, agglutination capacity and levels of MUC5AC and PS6B-specific IgG
were not significantly different between the three groups in nasal wash at baseline.
Neutrophil activity contributes to protection against establishment of colonization
in nasal clearers. Neutrophils are abundantly present in the adult human nose even in
the absence of pneumococcal colonization or symptoms (19). Neutrophils are activated
by bacterial encounter, releasing myeloperoxidase (MPO) during degranulation (26,
27). To investigate if neutrophil activity at the time of bacterial encounter can protect
against establishment of pneumococcal colonization, the abundance of neutrophils
and MPO levels were measured at baseline. Nasal immune and epithelial cells were
measured from nasal curettes from a subset of 40 volunteers (see Fig. S3A in the sup-
plemental material) (19, 28). The absolute number of activated neutrophils were identi-
fied by measuring CD66bHi granulocyte levels, a marker for neutrophil activation (29).
We also analyzed total number of granulocytes and the expression levels of CD66bHi
within the granulocyte population (Fig. S3A).
At baseline, nasal clearers had increased numbers of activated (CD66bHi) granulo-
cytes (median, 759; interquartile range [IQR]: 343 to 1,248) compared to those of cul-
ture-positives (median, 134; IQR: 64 to 171) from nasal curettes (Fig. 3A). Moreover,
total numbers of granulocytes were also increased (median, 5,978; IQR: 3,268 to 8,678)
in curettes of nasal clearers compared to those of culture-positives (median, 1,701; IQR:
589 to 2,261) (Fig. S3B). This finding was supported by increased MPO levels at baseline
in nasal wash in nasal clearers compared to those of culture-positives (Fig. 3B).
Moreover, the granulocytes of nasal clearers had increased expression of CD66b com-
pared to those of saliva clearers (Fig. S3C). There was a significant correlation between
numbers of CD66bHi granulocytes and MPO levels in nasal wash (Fig. 3C). Furthermore,
there was no significant difference in levels of any other measured cell type (B cells, T
cells, epithelial cells, and monocytes) between the three groups (Fig. S3D to G), indicat-
ing that increased levels of neutrophils at baseline are protective against pneumococ-
cal colonization in nasal clearers. Thus, high levels of neutrophils and MPO at baseline
are associated with protection against pneumococcal colonization.
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FIG 2 Kinetics of pneumococcal detection in nasal fluid following exposure. (A) Frequency of S. pneumoniae (Spn) DNA detection in nasal
fluid after challenge, stratified by final colonization status (determined by conventional bacterial culture methods). NLF samples were
(Continued on next page)
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A robust inflammatory response is associated with protection from colonization
in saliva clearers. To investigate whether a prompt immune response contributes to
protection from colonization by pneumococcus, we longitudinally measured the abun-
dance of 30 cytokines in nasal lining fluid using Luminex. In addition, we longitudinally
measured levels of MPO in nasal lining fluid in the first 48 h post exposure (Fig. 4A).
Similar to what we measured in nasal wash, MPO levels in nasal clearers were elevated
at baseline in nasal lining fluid. Levels of MPO remained the same during the first 2
days in nasal clearers. In saliva clearers and culture-positives, however, levels of MPO
rose after exposure and reached a significant peak at 24 h (Fig. 4A).
For the other 30 analyzed cytokines, there were no differences at baseline between
the three groups (see Fig. S4A in the supplemental material). However, distinct cyto-
kine profiles were observed over time within the three groups (Fig. 4B and C). Nasal
clearer volunteers had limited cytokine induction at any time point measured during
the first 48 h, with only monocyte chemoattractant protein 1 (MCP-1) and epidermal
growth factor (EGF) significantly induced at 24 h post exposure, after correction for
multiple testing. In contrast, saliva clearers and culture-positives showed a significant
induction of multiple cytokines at 24 h post exposure. Saliva clearers showed a signifi-
cant induction of 6 cytokines (interleukin-1b [IL-1b], EGF, MIP-1b/CCL4, hepatocyte
growth factor [HGF], MIP-1a/CCL3, and IL-8). Culture-positives showed significant
induction of 12 cytokines at this time point (Fig. 4B; IL-1b , EGF, MIG, IL-6, HGF, IL-12,
alpha interferon [IFN-a], MIP-1a/CCL3, vascular endothelial growth factor [VEGF], MCP-
1, tumor necrosis factor alpha [TNF-a], and eotaxin). At 48 h, no cytokines were signifi-
cantly increased compared to those at baseline in any of the groups, demonstrating a
transient response to S. pneumoniae exposure. A total cytokine induction score was cal-
culated by summing the Z-score normalized fold change for each of the measured
cytokines, similar to that which has previously been described for gene expression
(30). Based on this cytokine induction score, saliva clearers showed an increased
response upon exposure compared to that of nasal clearers and culture-positives
(Fig. 4C). Cytokines that were found to be increased in any condition at 24 h strongly
correlated with MPO production in nasal lining fluid at 24 h (Fig. S4B).
Thus, nasal clearers, who had increased neutrophil levels at baseline showed limited
cytokine responses upon exposure, while both saliva clearers and culture-positives
showed a transient but clear response upon exposure, which was significantly higher
in the saliva clearer group (Fig. 5).
DISCUSSION
To develop effective protective interventions against disease, it is vital to under-
stand which mechanisms play a crucial role in host-pathogen interactions by protect-
ing against the establishment of colonization following bacterial encounter. Here, we
investigated human-pneumococcus interactions in the first 48 h following controlled
intranasal exposure. We tested the hypothesis that volunteers who are susceptible to
colonization have a distinct profile of S. pneumoniae DNA kinetics and immune
responses in the nose and saliva from those in the culture-negative group in the first
hours and days after exposure.
Culture-positive volunteers showed no fast-initial clearance (appearance in saliva)
during the first hour following exposure (Fig. 5). Colonization took at least 24 h to be
FIG 2 Legend (Continued)
collected before (T=0) pneumococcal exposure and at 4, 8, 24, and 48h post exposure. The number of volunteers with S. pneumoniae 6B
presence in each time point is expressed as a percentage (%) of the total number of volunteers analyzed for culture-positives (red) and
culture-negatives (black). (B) Individual-level DNA detection results, grouped by culture-positives (red, n=20) and culture-negatives (n=39).
The latter group is subdivided into saliva clearers (blue, n=15) and nasal clearers (green, n=24). Samples not taken are highlighted in gray.
(C) Density levels of pneumococcal 6A/B PCR in NLF, expressed as DNA copies per nasosorption device. If no S. pneumoniae was detected,
the density was set as 0 CFU/ml. Data was log transformed after adding 1 to all values to allow transforming 0 values. Individual volunteers
and the mean of log-transformed values are shown. (D) Levels of agglutination capacity in nasal wash at baseline in initial cohort. Nine
culture-positive, 12 saliva clearer, and 17 nasal clearer volunteers were included in analysis. Each dot represents one volunteer. Mean 6
standard error of the mean (SEM) is shown for each of the three groups.
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FIG 3 Association of baseline mucosal immune factors with early pneumococcal colonization profiles. (A) Neutrophil
number in nasal scrapes prior to pneumococcal exposure. Abundance of CD66b-high cells (activated granulocytes) at
(Continued on next page)
Nikolaou et al. ®
January/February 2021 Volume 12 Issue 1 e02020-20 mbio.asm.org 8



























fully established, after which increased S. pneumoniae densities could be measured in
saliva. We also observed pneumococcal presence progressively diminishing in the an-
terior nose (exposure site) after 24 h, suggesting that migration toward the nasopha-
ryngeal site may take place by this time point. Alternatively, the absence of pneumo-
coccus from the anterior nose may reflect strong epithelium binding or even
internalization of the bacteria. Indeed, pneumococcus was found to attach to epithe-
lium of the inferior nasal turbinate in the EHPC model during colonization (31). One li-
mitation to our study is that it uses an experimental challenge of adults. Therefore,
findings might not be generalizable to infants or young children, as important differen-
ces in immune system and susceptibility to pneumococcus exist between adults and
children (32). Moreover, it is possible that colonization dynamics during experimental
challenge are different from those during natural exposure.
Nasal clearers showed a strong baseline neutrophil activation. These volunteers did
not develop a significant pro-inflammatory response or had bacterial movement to the
saliva within 1 h. It is possible that the high level of baseline activated nasal neutrophils
prevented sensing by epithelium or other cell types, such as monocytes, as well as
movement to the saliva. This indicates that neutrophils play a key role in the early con-
trol of human pneumococcal colonization. This has not been appreciated in murine
models of infections, as neutrophils are abundant in the nasal lumen of humans (33)
but not of naive mice (34) that show cellular influx only following bacterial challenge.
In agreement with our finding, the relative prevalence of pneumococcal serotypes in
causing colonization in the community associates with their relative capacities to resist
neutrophil-mediated killing in vitro (35).
Saliva clearers (around 40% of protected individuals) were defined by an initial fast
movement of the bacteria to the saliva. Although this was not associated with
increased agglutination capacity, this could still be due to effective nasal mucociliary
activity. Moreover, saliva clearers induced a strong proinflammatory response at 24 h
post exposure. This transient response suggests that in this group, similar to culture-
positives but not in nasal clearers, the inoculated bacteria is sensed, leading to an
induction of immunological responses. Although culture-positives showed more signif-
icantly increased cytokines at 24 h than saliva clearers (12 versus 6), the fold change
of induced cytokines was larger in the saliva clearers as reflected by the higher cyto-
kine induction score. Moreover, cytokines IL-8 and MIP-1b were only significantly
increased in the saliva clearer group. Taken together, this suggests that this group
could be protected by mucociliary clearance, which is then supported by an innate
response to pneumococcus.
FIG 3 Legend (Continued)
baseline were measured by flow cytometry. Eight culture-positives, 9 saliva clearers, and 14 nasal clearers were
assessed (*, P=0.018, unpaired t test). There is no statistically significant difference of the CD66bHi neutrophil counts
between nasal and saliva clearers (P=0.107, unpaired t test). Data were log transformed, and individual volunteers
and mean 6 SEM are represented. (B) MPO levels in nasal wash prior to pneumococcal exposure—both cohorts.
MPO levels at baseline were measured by ELISA. Twenty-one culture-positives, 16 saliva clearers, and 24 nasal
clearers were assessed. MPO levels in nasal wash were significantly increased in nasal clearers compared to those in
culture-positives (*, P=0.034, unpaired t test). Data were log transformed, and individual volunteers and mean 6
SEM are represented. (C) Correlation between MPO levels in nasal wash and number of activated granulocytes
(CD66bHi) in nasal scrapes prior to S. pneumoniae challenge for paired samples. Eight culture-positives, 9 saliva
clearers, and 14 nasal clearers were assessed (Pearson test, r=0.480; **, P=0.006). Data were log transformed.
Culture-positives, red circles; saliva clearers, blue rectangular; and nasal clearers, green squares. (D) MUC5AC in nasal
wash at baseline. Each dot represents a volunteer, and mean 6 SEM are shown. No statistical significance was
detected within the groups (unpaired t test, culture-positives versus saliva clearers, P=0.568; culture-positives versus
nasal clearers, P=0.112; saliva clearers versus nasal clearers, P=0.250). (E) Levels of S. pneumoniae 6B polysaccharide-
specific IgG (PS6B) antibodies in nasal wash at baseline. Each dot represents a volunteer, and mean 6 SEM are
shown. No statistical significance was detected within the groups (Mann-Whitney test, culture-positives versus saliva
clearers, P=0.722; culture-positives versus nasal clearers, P=0.118; saliva clearers versus nasal clearers, P=0.438). (F)
Agglutination capacity (%) versus mucin (MUC5AC) in nasal wash at baseline. Culture-positives, red circles (n=9);
saliva clearers, blue rectangular (n=7); and nasal clearers, green squares (n=12). Data were log transformed, and
Spearman rho and P values are depicted in addition to linear regression (black line). (G) Agglutination capacity (%)
versus S. pneumoniae 6B polysaccharide-specific IgG (PS6B) antibody levels in nasal wash at baseline. Culture-
positives, red circles (n=9); saliva clearers, blue rectangular (n=12); and nasal clearers, green squares (n=17). Data
were log transformed, and Spearman rho and P values are indicated.
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In conclusion, we described the dynamics of establishment of colonization by S.
pneumoniae in humans and observed that two different mechanisms were associated
with protection. This highlights that correlates of protection against pneumococcal col-
onization, which can be used to inform design and testing of novel vaccine candidates,
could be valid for subsets of protected individuals.
MATERIALS ANDMETHODS
Experimental design—recruitment of volunteers and ethical statements. Volunteers were en-
rolled from clinical studies conducted between 2016 and 2019. Details on study design have been previ-
ously described (36). Ethical approval was given by local NHS Research and Ethics Committee (REC) (14/
NW/1460, 18/NW/0481, 15/NW/0931), and the clinical trial was registered on the European Clinical Trials
Database (EudraCT, 2014-004634-26 and ISRCTN22467293). All experiments conformed to the relevant
regulatory standards (Human Tissue Act, 2004). Informed consent was obtained from all volunteers.
Briefly, volunteers were screened for S. pneumoniae colonization (natural carriers) and were intrana-
sally inoculated with the S. pneumoniae 6B serotype (strain BHN418; GenBank accession number
ASHP00000000.1) at 8 104 CFU/100ml per nostril. Colonization was assessed by classical microbiology
FIG 4 Nasal immune factors during the first 48 h post exposure. (A) MPO levels in nasal lining fluid during the
first 48 h measured by ELISA. Volunteer numbers assessed are indicated above the x axis per time point after
exposure. Data were log transformed, and individuals and mean 6 SEM are depicted. In culture-positives and
saliva clearers, levels of MPO rose after exposure, peaking at 24 h after pneumococcal exposure (*, P=0.016
and **, P=0.006, respectively; paired t test to baseline). MPO baseline levels are statistically significantly
different between nasal clearers and saliva clearers (*, P= 0.046, unpaired t test). (B) Cytokine profile heatmap
in nasal lining fluid following S. pneumoniae challenge within the three groups. Concentrations of 30 cytokines
was measured by Luminex at 4, 8, 24, and 48 h after pneumococcal exposure and normalized to baseline levels
for each subject. The mean of log2-tranformed fold changes are shown per time point for each of the three
groups. *, P, 0.05 based on paired t test comparing to baseline, followed by multiple testing correction
(Benjamini-Hochberg). (C) Cytokine induction score in nasal lining fluid following S. pneumoniae challenge. A
total cytokine induction score was calculated by summing the Z-score normalized to fold change for each of
the measured cytokines. Paired volunteer numbers to baseline are indicated per time point after exposure
(same numbers in Fig. 4B). Saliva clearers showed statistically significant total induction score of cytokines at
24 h postexposure compared to those of nasal clearers and culture-positives.
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culture in nasal washes collected at 2, 6, 9, 14, 21, and 27days post exposure, and serotype was con-
firmed by latex agglutination (Statens Serum Institut, Copenhagen, Denmark). Colonization results were
confirmed by S. pneumoniae 6A/B capsule-specific and lytA-specific qPCR on nasal wash pellet as
described below. Volunteers enrolled in home sampling were not vaccinated against S. pneumoniae.
Home sampling procedure. Volunteers were given written instruction sheets for sample self-collec-
tion and picture taking/sending via mobile messaging application plus a sample data collection form
(time planner). Volunteers were given a transport bag containing eight 10-ml saliva collection tubes and
funnels (plus one spare) (Isohelix; Cell Projects Ltd, Kent, UK) with 1 ml skim milk, tryptone, glucose, and
glycerin (STGG) medium with 50% glycerol for bacterial preservation and transport, 4 adsorptive matrix
filter strips (Nasosorption; Hunt Developments Ltd, West Sussex, UK) for nasal fluid collection, 2 ice packs
for keeping samples cooled during the day, 1 plastic box for sample storage, and a USB temperature
data logger thermometer (Woodley Equipment Company Ltd, Lancashire, UK) for temperature monitor-
ing. For nasal lining fluid collection, the matrix strip was inserted into the nostril and held against the
nasal lining for 2min and then placed in its transport tube. For saliva collection, volunteers spat up to
1ml of saliva into the STGG tube. Both sample collection methods were demonstrated to the volunteers
at baseline sample collection. Optimization experiments were performed to investigate optimal sample
storage conditions by spiking saliva with different S. pneumoniae concentrations. Results indicated that
S. pneumoniae density was lower in samples stored at ambient temperature; however, similar S. pneumo-
niae density was detected from samples stored either in a fridge or freezer. Samples taken were stored
in the volunteer’s home freezer overnight and transported to the lab at their day 2 clinic visit, where
they were immediately stored at280°C until use.
Bacterial DNA extraction from saliva samples. Bacterial genomic DNA was extracted from raw and
culture-enriched saliva samples. On the day of the extraction, saliva samples were thawed for 30 min at
room temperature and vigorously vortexed for 20 s. Two hundredmicroliters of raw saliva was used for
DNA extraction. In addition, for the culture enrichment step, 10ml of raw saliva was diluted with 90ml of
saline and cultured on Columbia blood agar supplemented with 5% horse blood (PB0122A; Oxoid/
Thermo Scientific) and 80ml gentamicin 1mg/ml (G1264-250mg; Sigma-Aldrich Co. Ltd). Plates were
incubated overnight at 37°C and 5% CO2. The remaining raw saliva was stored at 280°C. After incuba-
tion, all bacterial growth was harvested into 2ml STGG and vigorously vortexed until homogenized. Two
hundredmicroliters of culture-enriched saliva was used for DNA extraction, and the remaining samples
were stored at 280°C.
For both raw and culture-enriched saliva samples, thawed suspensions were pelleted in a 1.5-ml
FIG 5 Summary model of findings. Schematic drawings of the nasopharynx are depicted for the three groups
of individuals. Neutrophils, cytokines, and bacteria are depicted over time to illustrate the bacterial and
immunological kinetics upon pneumococcal exposure.
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tube at 20,238 g for 10min. The pellet was resuspended in 300ml of lysis buffer with protease (Agowa
Mag mini DNA extraction kit; LGC Genomics, Berlin, Germany), 100ml of sterilized zirconia/silica beads
(diameter of 0.1mm; BioSpec Products, Bartlesville, OK, USA), and 300ml of phenol (Phenol BioUltra;
Sigma-Aldrich, Zwijndrecht, The Netherlands). The sample was mechanically disrupted by bead beating
in a TissueLyser LT (Qiagen, Venlo, The Netherlands) twice at 50Hz for 3min. After 10min centrifugation
at 9,391  g, the aqueous phase was transferred to a sterile 1.5-ml tube. Binding buffer was added at
twice the volume of the aqueous phase plus 10ml of magnetic beads, after which the sample was incu-
bated in a mixing machine (;265 rpm) for 30min at room temperature. The magnetic beads were
washed with 200ml of both wash buffer 1 and wash buffer 2 and eluted with 63ml of elution buffer
according to the manufacturer's instructions. For optimization experiments, DNA from all raw saliva sam-
ples was also extracted using QIAamp DNA minikit (Qiagen, Manchester, UK) following manufacturer’s
instructions. This method showed the same results as the one described previously in this section.
Bacterial DNA extraction from nasal fluid pellet. On the day of the extraction, nasosorption filter
strips were thawed for 30min at room temperature. One hundredmicroliters of assay diluent was added
to the filter and centrifuged at 1,503  g for 10min. After centrifugation, the eluted liquid was moved to
a clean Eppendorf tube and centrifuged at 16,000  g for 10 min at 4°C. The supernatant was removed
and used for cytokine analysis, whereas the pellet was used for DNA extraction. Bacterial genomic DNA
was extracted from the nasal fluid pellets using the same method as described above (saliva samples).
Quantification of pneumococcal DNA by qPCR in saliva and nasal fluid pellet samples.
Colonization density was determined by 6A/B-specific qPCR targeting the CpsA gene using the
Mx3005P system (Agilent Technologies, Cheadle, UK). The primers and probe sequences were as follows:
forward primer, 59-AAGTTTGCACTAGAGTATGGGAAGGT-39; reverse primer, 59-ACATTATGTCCATGTCT
TCGATACAAG-39; and probe, 59-(FAM)-TGTTCTGCCCTGAGCAACTGG-(BHQ1)-39 (22). The 25-ml PCR mix
consisted of 12.5ml 1 TaqMan Universal PCR master mix (Life Technologies Ltd, Paisley, UK), 0.1ml
100mM each primer, 0.05ml 100mM probe, 9.75ml molecular graded water (Fisher Scientific,
Loughborough, UK), and 2.5ml of the extracted DNA. Thermal cycling conditions were as follows: 10min
at 95°C and 40 cycles of 15 s at 95°C and 1min at 60°C. A negative DNA extraction control (parallel
extraction from sample buffer only), a qPCR-negative control (master mix only), and three extractions of
each sample were amplified. A standard curve of a 10-fold dilution series of genomic DNA extracted
from S. pneumoniae 6B was used. The genomic DNA was extracted with the QIAamp DNA minikit
(Qiagen, Manchester, UK) and quantified with a spectrophotometer (NanoDrop ND-1000; Thermo Fisher
Scientific, Landsmeer, The Netherlands). To convert the weight of pneumococcal DNA to number of S.
pneumoniae DNA copies, the weight of one genome copy of TIGR4 was used to calculate the genome
length in base pairs times the weight of a DNA base pair (650Da). Samples were considered positive if
two or all triplicates yielded a CT value of ,40 cycles. Multiple experiment analysis was performed, and
cross experiment threshold was calculated by using interrun calibrators.
Humanmyeloperoxidase ELISA. Levels of myeloperoxidase were determined using the human my-
eloperoxidase DuoSet ELISA kit (R&D Systems, Abingdon, UK). Ninety-six-well enzyme-linked immuno-
sorbent assay (ELISA) plates were coated with 4mg/ml capture antibody in phosphate-buffered saline
(PBS) at room temperature (RT) overnight. Plates were washed 3 times with PBS (Sigma-Aldrich Co. Ltd,
Irvine, UK) containing 0.05% Tween 20 (Sigma-Aldrich Co. Ltd, Irvine, UK) between each step. Wells were
blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at RT. Samples and standards were diluted
in 1% BSA-PBS in the precoated plates and incubated at RT for 2 h. Detection was performed by incubat-
ing plates with detection antibody at 50 ng/ml for 2 h at RT, followed by 20min incubation with strepta-
vidin-horseradish peroxidase (HRP) (1:200) (Fisher Scientific, Loughborough, UK) at RT. Signal was devel-
oped using TMB-Turbo substrate (Fisher Scientific, Loughborough, UK) for 20min and stopped by
adding 2 N H2SO4 in a 1:1 ratio. Optical density reading was performed at 450 nm and corrected for opti-
cal imperfection (540 nm). All samples were run in duplicate. Results are expressed as micrograms per
milliliter and calculated using an MPO standard curve.
Agglutination assay by flow cytometry. S. pneumoniae 6B cells were grown to mid-log phase and
stored at 280°C in glycerol until use as described previously (23). For agglutination assays with human
nasal wash samples, cells were thawed and washed with PBS, and 4 105 CFU bacteria in 2ml saline was
incubated with 48ml of concentrated nasal wash supernatant (1ml of nasal wash concentrated to 50ml
using vacuum concentrator RVC 2-18) and dialyzed overnight in PBS using Slide-A-Lyzer dialysis units
(Thermo Fisher). Antiserum to group 6 (Statens Serum Institut; Neufeld antisera to group 6) was used as
a positive control and anti-Hep-A purified human IgG was used as a negative control (using Sepharose
and pooled sera from HepA-vaccinated volunteers). Samples were vortexed lightly and incubated for 1.5
h at 37°C and 5% CO2.
Cells were fixed with paraformaldehyde (PFA) and analyzed on a BD LSR II flow cytometer (BD
Biosciences, San Jose, CA, USA). Bacterial population was gated in the forward scatter (FSC) and sideward
scatter (SSC) dot plot referring to cell size and granularity. Photomultiplier tubes (PMT) voltages and
threshold were gated on negative control bacteria. A total of 30,000 events for each sample were meas-
ured by triplicate using FacsDiva software 6.1 (BD Biosciences, San Jose, CA, USA). Agglutination was quan-
tified by calculating the proportion of the bacterial population with altered FSC and SSC, and values were
expressed as percentage of agglutination as previously described (37). All samples were analyzed in dupli-
cate, and 30,000 events were acquired using FacsDiva software 6.1 (BD Biosciences, San Jose, CA, USA).
Analysis was performed using FlowJo software version 10.0 (Tree Star Inc., San Carlos, CA, USA).
Nasal cells processing and flow cytometry. Cells were dislodged from the curette by repeated
pipetting with PBS1 as described previously (19, 27). Cells were spun down at 440  g for 5min and
resuspended in PBS11 containing LIVE/DEAD fixable aqua dead cell stain (Thermo Fisher). After 15min
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incubation on ice, an antibody cocktail, which included EpCam-PE, HLADR-PECy7, CD66b-FITC, CD19-
BV650 (all BioLegend), CD3-APCCy7, CD14-PercpCy5.5 (BD Biosciences), and CD45-PACOrange (Thermo
Fisher), was added to the cells. Following a further 15-min incubation on ice, cells were filtered over a
70-mm filter (Thermo Fisher). Cells were spun down (440  g for 5min), resuspended in PBS containing
0.5% heat-inactivated fetal bovine serum and 5mM EDTA (Invitrogen), and acquired on a flow cytometer
(LSR II; BD). All cells per tube were acquired, and samples with less than 500 immune cells or 250 epithe-
lial cells were excluded from further analysis (9/40 samples; 22.5%). The numbers of acquired cells per
population were used as counts. Flow cytometry data were analyzed using FlowJo version 10 (Tree Star
Inc., San Carlos, CA, USA).
Cytokine analysis. Nasal washes were centrifuged at 1,503  g for 10 min, and the extracted super-
natant was stored at 280°C until use. Human MPO was measured according to the manufacturer’s
instructions. The human magnetic 30-plex cytokine kit (Thermo Fisher) was used to detect 30 cytokines
simultaneously on an LX200 with xPonent 3.1 software (Luminex) following manufacturer’s instructions
from centrifuged nasal lining fluid. Analytes with a coefficient of variation (CV) of .50% were excluded
from further analyses. One Luminex plate did not pass quality control, and samples with remaining vol-
ume were reanalyzed.
Heatmap generation and total cytokine score. Heat map representations were generated using R.
Fold change concentrations to baseline were calculated for each individual and log2 transformed. An av-
erage fold change for each group for each time point was then calculated. A total cytokine score was
calculated as previously described (30). In brief, Z-scores of fold changes for all upregulated cytokines
for a given individual were calculated by replacing downregulated cytokines with a value of 0 and then
summing the Z-scores per sample.
Quantification and statistical analysis. Statistical analysis was performed using GraphPad Prism
version 5.0 (CA, USA) and R software. Data was log transformed where appropriate. To distinguish
between parametric and nonparametric data, a Kolmogorov-Smirnoff test was performed. If two para-
metric groups were compared, a two-tailed t test was used for unpaired and paired groups. If two non-
parametric groups were compared, a Mann-Whitney or Wilcoxon test was used for unpaired and paired
groups, respectively. If multiple unmatched groups were compared, a one-way analysis of variance
(ANOVA) (followed by a Tukey’s posttest) or Kruskal-Wallis test (followed by a Dunn’s posttest) was used
for parametric or nonparametric groups, respectively. For Luminex data, a Benjamini-Hochberg correc-
tion was used to account for testing of 30 cytokines simultaneously. To quantify association between
groups, a Pearson or Spearman correlation test was used for parametric or nonparametric groups,
respectively. Differences were considered significant if Pwas,0.05.
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